Table 1 Clinicopathological parameters from 122 of the 125 prostatic adenocarcinoma patients
Clinicopathological parameters | Number of cases | TMPRSS2:ERG | P-value | |
|---|---|---|---|---|
Not fused | Fusion | |||
Preoperative PSA (ng/ml) a | 0.612 | |||
0.9–4.0 | 9 | 3 (33.33) | 6 (66.67) | |
4.0–10.0 | 58 | 31 (53.45) | 27 (46.55) | |
10.1–20.0 | 37 | 21 (56.76) | 16 (43.24) | |
20.1–84.0 | 15 | 7 (46.67) | 8 (53.33) | |
Median tumor volume (%) a | 0.886 | |||
0–10.0 | 35 | 19 (54.29) | 16 (45.71) | |
10.1–20.0 | 28 | 14 (50.00) | 14 (50.00) | |
20.1–85.0 | 49 | 24 (48.98) | 25 (51.02) | |
Gleason score | 0.636 | |||
4–6 | 74 | 39 (52.70) | 35 (47.30) | |
7 | 35 | 18 (51.43) | 17 (48.57) | |
8–9 | 13 | 5 (38.46) | 8 (61.54) | |
Pathologic stage | 0.966 | |||
pT2a | 10 | 6 (60.00) | 4 (40.00) | |
pT2b | 58 | 30 (51.72) | 28 (48.28) | |
pT3a | 39 | 19 (48.72) | 20 (51.28) | |
pT3b | 9 | 4 (44.44) | 5 (55.56) | |
pT4 | 6 | 3 (50.00) | 3 (50.00) | |
Seminal vesicle invasion a | 0.337 | |||
Negative | 108 | 54 (50.00) | 54 (50.00) | |
Positive | 9 | 6 (66.67) | 3 (33.33) | |
Perineural infiltration | 0.344 | |||
Negative | 18 | 11 (61.11) | 7 (38.89) | |
Positive | 104 | 51 (49.04) | 53 (50.96) | |
Angiolymphatic invasion a | 0.400 | |||
Negative | 89 | 43 (48.31) | 46 (80.70) | |
Positive | 26 | 15 (57.69) | 11 (19.30) | |
Capsular invasion a | 0.387 | |||
Negative | 52 | 29 (55.77) | 23 (44.23) | |
Positive | 69 | 33 (47.83) | 36 (52.17) | |
Extraprostatic extension a | 0.835 | |||
Negative | 92 | 46 (50.00) | 50 (50.00) | |
Positive | 19 | 9 (47.37) | 10 (52.63) | |
Lymphonodal invasion a | 0.154 | |||
Negative | 108 | 53 (49.07) | 55 (50.93) | |
Positive | 2 | 2 (100.00) | 0 (0.00) | |
Biochemical recurrence | 0.047 | |||
Negative | 62 | 37 (59.68) | 25 (40.32) | |
Positive | 60 | 25 (41.67) | 35 (58.33) | |
